Respiratory
Seyltx buys Algernon’s Phase II chronic cough therapy
US-based Seyltx has closed an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received a purchase price…
AstraZeneca kick-starts Phase III COPD trial for Breztri
AstraZeneca has launched a Phase III THARROS trial to evaluate the efficacy of its triple-combination inhaled therapy Breztri (budesonide /…
Upstream Bio doses first patients in Phase II asthma trial
Upstream Bio has announced the commencement of patient dosing in its Phase II VALIANT clinical trial of verekitug (UPB-101) for…
Innovent Biologics doses first subject in Phase I asthma treatment trial
Innovent Biologics has dosed the first subject in a first-in-human Phase I trial of IBI3002 to treat asthma. The double-blind,…
ReAlta begins subject enrolment in Phase II trial of AE-COPD treatment
ReAlta Life Sciences has enrolled the first subject in a Phase II clinical trial of its investigational drug RLS-0071, aimed…
Vertex hopes to fast-track approval of CF therapy on heels of positive Phase III data
Vertex Pharmaceuticals will be using its priority review voucher with the US Food and Drug Administration (FDA) with hopes of…
ECDC report suggests respiratory infections could surge this winter
Bacterial and viral respiratory infections contribute to morbidity and mortality every winter. Those over the age of 65 years have…
Clarametyx launches Phase Ib/IIa cystic fibrosis therapy trial
US-based Clarametyx Biosciences is starting the enrolment for its Phase Ib/IIa trial investigating CMTX-101 as an adjunctive therapy for patients…
Ethris doses first patient with antiviral mRNA drug in Phase I asthma trial
Ethris has dosed the first participant with its inhaled mRNA therapy ETH47 as part of a Phase I trial evaluating…
MHRA approves Ethris’ Phase I trial for inhaled mRNA drug
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ethris’s Phase I trial to investigate its inhaled mRNA…
